The primary analysis of the phase 2 LYRA trial was previously reported after all patients completed 4 cycles of daratumumab plus CyBorD induction therapy. For that analysis, the rate of VGPR or better was 44.2% for patients with newly diagnosed multiple myeloma and 57.1% for patient...
(7.8 % vs 4.3 %). On January 15th, 2021, based on the propitious results of the ANDROMEDA trial, daratumumab was granted accelerated approval in combination with CyBorD for newly diagnosed AL amyloidosis (Center for Drug Evaluation and Research, 2021). Preliminary results from two phase 2 ...
Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)Background: Dara, a human IgGκ monoclonal antibody that targets CD38, is approved in combination with bortezomib, ...
Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM) Background: Dara, a human IgGκ monoclonal antibody that targets CD38, is approved in combination with bortezomib, ...
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020;2;136(1):71-80. 12 Chari A, et al. Daratumumab plus pomalidomide and dexamethasone in rela...
·52) Tongue 20% Nerve 30% Gastrointestinal 15% Prior treatment Prior cyclophosphamide/bortezomib/dexamethasone (CyBorD) 65% Prior immunomodulatory drugs (pomalidomide and lenalidomide) 60% Prior carfilzomib 20% Prior ixazomib 35% Prior high dose melphalan and AHCT 65% Reason for DARA initiation ...
S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN-IN RESULTS OF ANDROMEDAdoi:10.1097/01.HS9.0000561780.07253.e5Comenzo, R.L....
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: Safety run-in results of ANDROMEDA 2020, Blood Show abstract Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment 2022, American Journal of Hematology Marked progress in AL amyloidosis survival...
These findings provide a rationale for the efficacy observed to date when combining Cy with Dara in the ongoing CyBorD-DARA clinical trial. Additionally, increases in BCMA and SLAMF7 highlight the potential of other combination immune therapies to further enhance therapeutic efficacy in these ...
Is maintenance with daratumumab needed in subjects who respond to daratumumab-CyBorD? In general, there are no data to support maintenance treatment in AL amyloidosis. This can be reasonable in patients who fulfil the criteria for multiple myeloma. However, unfortunately, the ANDROMEDA study was not...